Platelets, Endothelial Cells, Inflammatory Chemokines, and Restenosis
2002; Lippincott Williams & Wilkins; Volume: 106; Issue: 12 Linguagem: Inglês
10.1161/01.cir.0000033634.60453.22
ISSN1524-4539
AutoresAndrew S. Weyrich, Stephen M. Prescott, Guy A. Zimmerman,
Tópico(s)Protease and Inhibitor Mechanisms
ResumoHomeCirculationVol. 106, No. 12Platelets, Endothelial Cells, Inflammatory Chemokines, and Restenosis Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBPlatelets, Endothelial Cells, Inflammatory Chemokines, and RestenosisComplex Signaling in the Vascular Play Book Andrew S. Weyrich, Stephen M. Prescott and Guy A. Zimmerman Andrew S. WeyrichAndrew S. Weyrich From the Department of Internal Medicine (A.S.W., S.M.P., G.A.Z.), The Huntsman Cancer Institute (S.M.P.), and The Program in Human Molecular Biology and Genetics (A.S.W., G.A.Z.), The University of Utah, Salt Lake City. , Stephen M. PrescottStephen M. Prescott From the Department of Internal Medicine (A.S.W., S.M.P., G.A.Z.), The Huntsman Cancer Institute (S.M.P.), and The Program in Human Molecular Biology and Genetics (A.S.W., G.A.Z.), The University of Utah, Salt Lake City. and Guy A. ZimmermanGuy A. Zimmerman From the Department of Internal Medicine (A.S.W., S.M.P., G.A.Z.), The Huntsman Cancer Institute (S.M.P.), and The Program in Human Molecular Biology and Genetics (A.S.W., G.A.Z.), The University of Utah, Salt Lake City. Originally published17 Sep 2002https://doi.org/10.1161/01.CIR.0000033634.60453.22Circulation. 2002;106:1433–1435Adhesive and signaling interactions between endothelial cells and leukocytes are key mechanisms that mediate both targeting of the blood cells to specific sites and information transfer that results in change in their phenotypes and function.1 These events are beneficial in defense against microbes and wound surveillance and repair; however, in dysregulated inflammatory conditions such as atherosclerosis and its complications, including acute coronary syndromes and restenosis after interventional procedures, accumulation and activation of leukocytes can injure the host. The cell–cell interactions and signaling mechanisms are complex in the game of inflammation, and there are a number of players. In addition to endothelial cells and leukocytes, platelets contribute to leukocyte accumulation and to changes in their behavior in both physiological and pathological conditions,2,3,4 emphasizing the intimate relationship between the thrombotic and inflammatory systems.See p 1523One mechanism involves direct adhesion of activated platelets to monocytes, neutrophils, or other leukocyte subclasses and binding of chemokines or lipid signaling molecules that are released from the platelets or displayed in a juxtacrine fashion on their surfaces (see below), to receptors on the leukocyte plasma membrane.3,5 In this issue of Circulation, Schober and co-workers6 report a different play in the inflammatory repertoire: platelets interacting with inflamed endothelial cells donate the CC chemokine regulated upon activation normal T cell expressed presumed secreted (RANTES) to the endothelial surface, where it acts as a cell-associated signal for adhesion of monocytes. A number of the observations were made with cultured endothelial monolayers, incubated under conditions of stasis or flow, and isolated leukocytes; a caveat is that these experiments were done with proprietary endothelial cells and a monocytic cell line rather than primary leukocytes. In addition, however, other strategies added to the findings. Receptor blocking experiments indicated that RANTES signaling contributes to intimal hyperplasia and macrophage accumulation in an in vivo model of restenosis in atherosclerosis-prone apolipoprotein (apoE)-deficient mice.6 Interestingly, the transfer of RANTES from platelets to the endothelial plasma membrane seems not to require tight adhesion between these two cells. Instead, it appears to be a "give and go" mechanism that involves transient interaction of the two cells that is nonetheless sufficient for delivery of the chemokine. In vivo experiments using P-selectin–deficient mice crossed to apoE-deficient animals in parallel with in vitro assays indicated that P-selectin is required for monocyte and macrophage accumulation and intimal hyperplasia.6 This is not unexpected, since P-selectin mediates adhesion, signaling, and gene expression when the ligand for P-selectin on monocytes and other leukocytes, P-selectin glycoprotein ligand-1 (PSGL-1), is engaged by P-selectin that is displayed by activated endothelial cells or platelets.1–5,7 In addition, P-selectin is critical for intimal hyperplasia in other murine models of vascular injury.3,6,8 The surprise is that in the experiments reported by Schober et al,6 platelet P-selectin was required for transfer of RANTES to the endothelial surface, whereas P-selectin on endothelial cells was not involved. In this vascular game involving three franchise players — endothelial cells, platelets and leukocytes — the "give and go" route is complex indeed when the RANTES signal is called.Signaling of leukocytes by factors localized on the surfaces of endothelial cells has been known for some time. The first mechanism to be reported was binding of platelet-activating factor (PAF), a phospholipid, to its receptor on target neutrophils (PMNs) while associated with the plasma membranes of endothelial cells. This signaling event triggers spatially-regulated activation of the PMNs and a variety of responses, including activation of β2 integrins, which mediates tight adhesion of the leukocytes to the endothelial surface.1,4 PAF is rapidly synthesized by endothelial cells stimulated with thrombin or other agonists, and is translocated to the endothelial plasma membrane but retained there rather than being released into solution. Thus, this is a juxtacrine mechanism in which a signaling molecule is recognized by its receptor on a "target" cell and activates it, while remaining associated with the cell of origin.1,4 In this case the signaling molecule is PAF, and the signaling cell is an inflamed or injured endothelial cell. PAF can also signal PMNs in a juxtacrine fashion when it is synthesized and displayed on the surfaces of adherent activated platelets in models of thrombosis and its inflammatory sequellae.4 When PAF signals PMNs in a juxtacrine fashion at the surfaces of stimulated endothelial cells or platelets, it acts in cooperation with P-selectin, which is simultaneously displayed on these cells and is required for tethering of the target PMN.1,4In addition to PAF, chemokines can engage their receptors and send outside-in signals while displayed on cellular surfaces. The earliest examples involved the C-X-C chemokine interleukin-8, and were again mechanisms for spatially-localized signaling and activation of PMNs.1,9 Subsequently, RANTES was shown to have the capacity to signal monocytes, which bear the CCR1 and CCR5 receptors that recognize it, when immobilized on the surfaces of endothelial cells and to promote monocyte migration by haptotaxis when localized in this fashion.10 In this study, in situ hybridization failed to detect mRNA for RANTES in inflamed endothelial cells in tissue biopsies, however, suggesting that the chemokine was released by another cell type and was then bound by endothelium. The article by Schober et al6 in this issue, as well as an earlier report from this group, indicate that platelets can donate RANTES to endothelial cells for presentation to monocytes and that it can activate the leukocytes under conditions of flow while displayed at the endothelial surface.6 Thus, this is different from the juxtacrine mechanism outlined above because the signaling molecule, RANTES, is passed from one blood cell — the platelet — to the endothelial surface to be used to activate another intravascular cell type — the monocyte. Platelets are known to store RANTES in intracellular granules in the basal state and to release it when activated.2,11 However, the pass from platelets to endothelial cells in the current report is not a "long bomb" in which RANTES circulates over distance but rather a shuttle transfer that requires transient adhesion involving P-selectin.6 In addition, the endothelial cells must be appropriately conditioned to receive the inflammatory chemokine: deposition of RANTES on cultured endothelial cells required prior stimulation of the endothelial monolayers with interleukin 1β (IL-1β).While there are several potential sources of IL-1β in the inflammatory and atherosclerotic milieu, this is another pass that platelets can make. Human platelets activated by thrombin or PAF release IL-1β in microvesicles and soluble form in sufficient quantities to induce inflammatory gene expression in endothelial cells.12–14 This involves a previously-unrecognized ability of activated platelets to synthesize IL-1β and certain other proteins from constitutive messenger RNAs.14 The change in the surfaces of endothelial cells stimulated by IL-1β that allows them to capture and present RANTES to monocytes is not clear.6 The CC chemokine receptors that recognize RANTES were not present on IL-1–stimulated endothelial cells, excluding one possibility. In addition, there is a more likely group of candidate molecules. RANTES and several other chemokines are localized to cell surfaces and immobilized on extracellular matrix by binding to glycosaminoglycans via heparin recognition motifs,1,9,15 a feature of the endothelial surface that may be altered by cytokine activation.Although signaling of target leukocytes by chemokines and PAF presented at endothelial surfaces is of considerable interest in the context of mechanisms of restenosis, as well as for trafficking and accumulation of monocytes earlier in atherogenesis and for neutrophil activation in acute coronary syndromes, these are not the only pathological situations in which this mechanism may be important. A similar mechanism has been proposed in other syndromes of inflammation and vascular pathology,4,6,10 and chemokine presentation at endothelial surfaces may mediate tumor cell metastasis.16 There are important corollaries to this mode of intercellular signaling. One is that it may be difficult to detect it in vivo, and the concentrations of chemokines or other signaling molecules in solution may have little or no relationship to their actions when they are signaling while associated with cellular surfaces. Another is that activation of target cells by signaling molecules localized to cell surfaces may be more difficult to inhibit than when they are presented to their receptors in solution.4In the study of platelet–endothelial interactions,6 the mechanisms of transfer of RANTES and the identity of its binding sites on the endothelial surface are not the only questions that emerge from watching the "give and go" replays. The experiments indicated to the authors that transient adhesion between platelets and endothelial cells that is dependent on platelet P-selectin allows sufficient contact for deposition of RANTES, and that this is facilitated by flow. The nature of the binding partner for P-selectin on the endothelial surface was not defined and blocking experiments excluded the best characterized ligand, PSGL-1, as being important in the RANTES transfer. PSGL-1 is dominantly expressed by myeloid leukocytes, so this is not a surprise, although it has recently been reported to be present on platelets at low levels.3 However, this leaves the identity of alternative endothelial ligands that recognize P-selectin and facilitate transfer of RANTES unknown. Evidence that platelets specifically tether to the surfaces of endothelial cells, even transiently, has been reported only relatively recently in contrast to their well-characterized binding to sub-endothelial matrix proteins exposed by wounding or interventional manipulation.3,5,8 Endothelial cells have several mechanisms that inhibit platelet adhesiveness, including the ability to synthesize prostacyclin, prostaglandin E2 and nitric oxide, and conversely do not have known constitutive adhesive systems for platelets on their surfaces. Thus, stimulation of endothelial cells with IL-1β and their conversion to a prothrombotic and proinflammatory phenotype is likely to again be a key requirement, regardless of the identity of the binding site(s) that recognize platelet P-selectin. Other questions also come to mind. In the P-selectin/apoE –deficient animal model used in the study,6 it seems possible that uptake of RANTES into alpha granules of maturing platelets may have been reduced or eliminated because of interruption of key cell-cell interactions dependent on P-selectin at the megakaryocyte stage. While this would be an unexpected and cryptic explanation for the in vivo findings, it would be of interest for this and similar models and could be examined by assaying RANTES in platelets from P-selectin knockout mice. Other unknowns in the study include the requirements and roles of chemokines that are endogenously synthesized by inflamed endothelial cells, in addition to RANTES transferred from platelets, in promoting monocyte accumulation and macrophage differentiation in postinterventional restenosis. Treatment of apoE-deficient mice with a competitive antagonist of the RANTES receptor reduced neointimal macrophage infiltration and restenotic lesion formation by 40%, suggesting that other signaling molecules and intercellular interactions are also important. Furthermore additional chemokines, including monocyte chemotactic protein 1 (MCP-1), have been implicated in studies of human and experimental restenosis.17,18A growing body of evidence indicates that inflammation is a critical feature of postintervention restenosis in animal models6,8,18 and in vessels of human patients subjected to angioplasty and stenting.17,19 This involves more than targeting of monocytes to restenotic sites, which RANTES appears to facilitate in the "give and go" play between platelets and endothelium. There are also changes in phenotype, function, and gene expression in adherent monocytes, both acutely and as they differentiate into macrophages. These inflammatory responses, too, are modulated by RANTES and P-selectin, underscoring that these factors influence many cellular events in monocytes and macrophages in addition to their localization. A prime opportunity for signaling of new gene expression occurs when platelets adhere directly to monocytes or other leukocytes at sites of vascular injury.2,4,5,7,8 Interestingly, specific gene products expressed by adherent activated monocytes are under differential transcriptional and post-transcriptional control,2,4,5,7 including a subset of mRNAs that is regulated by mammalian target of rapamycin (mTOR).7 Thus, interruption of inflammatory signaling and gene expression, in addition to inhibiting smooth muscle proliferation and migration, may be a component of the beneficial effect of rapamycin, a new player in the defensive armamentarium against restenosis.20 This emphasizes the importance of knowing the diverse signaling mechanisms in the vascular play book for devising new therapies and understanding their mechanisms of action. The contributions of RANTES to inflammatory signaling of gene expression in target monocytes when it is displayed on the surfaces of endothelial cells after the "give and go" play6 compared with its direct pass off from platelets that are adherent to monocytes via P-selectin and PSGL-12 remains to be explored. Presentation of RANTES at the endothelial surface may occur relatively late after interventional injury to the vessel,6 whereas interaction of platelets and monocytes can occur quite early8. Both the timing and the molecular context of the signaling event (ie, the other chemokines and signaling factors presented to the monocyte in sequence and parallel to RANTES) will likely change the outcome of the play and the patterns of genes and other responses that are triggered.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.FootnotesCorrespondence to Guy Zimmerman, Program in Human Molecular Biology and Genetics, Eccles Institute of Human Genetics, 15 N 2030 East, Bldg. 533, Rm. 4220, University of Utah, Salt Lake City, UT 84112. E-mail [email protected] References 1 Zimmerman GA, McIntyre TM, Prescott SM. Adhesion and signaling in vascular cell–cell interactions. J Clin Invest. 1996; 98: 1699–1702.CrossrefMedlineGoogle Scholar2 Weyrich AS, Elstad MR, McEver RP, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest. 1996; 97: 1525–1534.CrossrefMedlineGoogle Scholar3 McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost. 2001; 86: 746–756.CrossrefMedlineGoogle Scholar4 Dixon DA, McIntyre T, Prescott SM, et al. Molecular mechanisms of juxtacrine cell signaling in microvascular responses and inflammation. In: G. Schmid-Schonbein, DN Granger, eds. Molecular Mechanisms of Microvascular Disorders. Paris, France: Springer-Verlag, 2002. In press.Google Scholar5 Galt SW, Lindemann SL, Medd D, et al. Differential regulation of matrix mellatoproteinase-9 by monocytes adherent to collagen and platelets. Cir Res. 2001; 89: 509–516.CrossrefMedlineGoogle Scholar6 Schober A, Manka D, von Hundelshausen BS, et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointimal formation after arterial injury. Circulation. 2002; 106: 1523–1529.LinkGoogle Scholar7 Mahoney TS, Weyrich AS, Dixon DA, et al. Cell adhesion regulates gene expression at translational checkpoints in human myeloid leukocytes. Proc Natl Acad Sci U S A. 2001; 98: 10284–10289.CrossrefMedlineGoogle Scholar8 Smyth SS, Reis ED, Zhang W, et al. β3-integrin–deficient mice but not P-selectin–deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 hour after injury. Circulation. 2001; 103: 2501–2507.CrossrefMedlineGoogle Scholar9 Rot A. Endothelial cell binding of NAP-1/IL-8: role in neutrophil emigration. Immunol Today. 1992; 13: 291–294.CrossrefMedlineGoogle Scholar10 Wiedermann CJ, Kowald E, Reinisch N, et al. Monocyte haptotaxis induced by RANTES chemokine. Current Biology. 1993; 3: 735–739.CrossrefMedlineGoogle Scholar11 Kameyoshi Y, Dorschner A, Mallet AI, et al. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med. 1992; 176: 587–592.CrossrefMedlineGoogle Scholar12 Hawrylowicz CM, Santoro SA, Platt FM, et al. Activated platelets express IL-1 activity. J Immunol. 1989; 143: 4015–4018.MedlineGoogle Scholar13 Loppnow H, Bil R, Hirt S, et al. Platelet-derived interleukin-1 induces cytokine production, but not proliferation of human vascular smooth muscle cells. Blood. 1998; 91: 134–141.CrossrefMedlineGoogle Scholar14 Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol. 2001; 154: 485–490.CrossrefMedlineGoogle Scholar15 Proudfoot AE, Fritchley S, Borlat F, et al. The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J Biol Chem. 2001; 276: 10620–10626.CrossrefMedlineGoogle Scholar16 Murphy PM. Chemokines and the molecular basis of cancer metastasis. N Engl J Med. 2001; 345: 833–835.CrossrefMedlineGoogle Scholar17 Cipollone F, Marini M, Fazia M, et al. Circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol. 2001; 21: 327–334.CrossrefMedlineGoogle Scholar18 Schmidt AM, Stern DM. Chemokines on the rise: MCP-1 and restenosis. Arterioscler Thromb Vasc Biol. 2001; 21: 297–299.CrossrefMedlineGoogle Scholar19 Farb A, Weber DK, Kolodgie FD, et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002; 105: 2974–2980.LinkGoogle Scholar20 Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med,. 2002; 346: 1773–1780.CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Qu S, Hu Z, Zhang Y, Wang P, Li S, Huang S, Dong Y, Xu H, Rong Y, Zhu W, Tang B and Zhu J (2022) Clinical Studies on Platelet-Rich Plasma Therapy for Chronic Cutaneous Ulcers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Advances in Wound Care, 10.1089/wound.2020.1186, 11:2, (56-69), Online publication date: 1-Feb-2022. Benjamin B, Lu W, Han Z, Pan L, Wang X, Qin X, Sun G, Wang X, Shan Y, Li R, Zheng X, Zhang W, Shi Q, Zhou S, Guo S, Qin P, Singh C, Dong J, Qiu C and Nguyen T (2021) Drug-Coated Balloon-Only Angioplasty Outcomes in Diabetic and Nondiabetic Patients with De Novo Small Coronary Vessels Disease, Journal of Interventional Cardiology, 10.1155/2021/2632343, 2021, (1-9), Online publication date: 1-Dec-2021. Díaz-Flores L, Gutiérrez R, García M, González-Gómez M, Díaz-Flores L, Gayoso S, Carrasco J and Álvarez-Argüelles H (2021) Ultrastructural Study of Platelet Behavior and Interrelationship in Sprouting and Intussusceptive Angiogenesis during Arterial Intimal Thickening Formation, International Journal of Molecular Sciences, 10.3390/ijms222313001, 22:23, (13001) Yushkov B (2021) Platelets and regeneration, Bulletin of Siberian Medicine, 10.20538/1682-0363-2021-2-216-227, 20:2, (216-227) Benjamin B, Qiu C, Han Z, Lu W, Sun G, Qin X, Wang X, Wang X, Li R, Pan L and Cardoso C (2021) The Association between Type-2 Diabetes Duration and Major Adverse Cardiac Events after Percutaneous Coronary Intervention, Journal of Diabetes Research, 10.1155/2021/7580486, 2021, (1-9), Online publication date: 25-Jan-2021. Sadowska B, Micota B, Różalski M, Redzynia M and Różalski M (2017) The immunomodulatory potential of Leonurus cardiaca extract in relation to endothelial cells and platelets , Innate Immunity, 10.1177/1753425917691116, 23:3, (285-295), Online publication date: 1-Apr-2017. Rainys D, Samulėnas G, Kievišas M, Samulėnienė E, Pilipaitytė L and Rimdeika R (2017) Platelet biology and the rationale of PRP therapy in chronic wounds, European Journal of Plastic Surgery, 10.1007/s00238-017-1279-x, 40:2, (87-96), Online publication date: 1-Apr-2017. Mahadevan A and Krishna S (2017) Perspectives on the Vascular Pathogenesis of Diabetic Neuropathy Mechanisms of Vascular Defects in Diabetes Mellitus, 10.1007/978-3-319-60324-7_10, (249-272), . Slaba I and Kubes P (2017) Platelets and Immunity Platelets in Thrombotic and Non-Thrombotic Disorders, 10.1007/978-3-319-47462-5_34, (489-512), . Alexandru N, Badila E, Weiss E, Cochior D, Stępień E and Georgescu A (2016) Vascular complications in diabetes: Microparticles and microparticle associated microRNAs as active players, Biochemical and Biophysical Research Communications, 10.1016/j.bbrc.2016.02.038, 472:1, (1-10), Online publication date: 1-Mar-2016. Yazdani N, Mojbafan M, Taleba M, Amiri P, Nejadian F, ashtiani M and Amoli M (2014) Sex-specific association of RANTES gene −403 variant in Meniere's disease, European Archives of Oto-Rhino-Laryngology, 10.1007/s00405-014-3151-y, 272:9, (2221-2225), Online publication date: 1-Sep-2015. Guzel Y, Karalezli N, Bilge O, Kacira B, Esen H, Karadag H, Toker S, Göncü R and Doral M (2013) The biomechanical and histological effects of platelet-rich plasma on fracture healing, Knee Surgery, Sports Traumatology, Arthroscopy, 10.1007/s00167-013-2734-2, 23:5, (1378-1383), Online publication date: 1-May-2015. Ikhapoh I, Pelham C and Agrawal D (2015) Sry-type HMG box 18 contributes to the differentiation of bone marrow-derived mesenchymal stem cells to endothelial cells, Differentiation, 10.1016/j.diff.2015.03.003, 89:3-4, (87-96), Online publication date: 1-Mar-2015. Ueba T, Nomura S, Inami N, Yokoi T and Inoue T (2014) Elevated RANTES Level Is Associated With Metabolic Syndrome and Correlated With Activated Platelets Associated Markers in Healthy Younger Men, Clinical and Applied Thrombosis/Hemostasis, 10.1177/1076029612467845, 20:8, (813-818), Online publication date: 1-Nov-2014. Hyacinth H, Adams R, Voeks J, Hibbert J and Gee B (2013) Frequent red cell transfusions reduced vascular endothelial activation and thrombogenicity in children with sickle cell anemia and high stroke risk, American Journal of Hematology, 10.1002/ajh.23586, 89:1, (47-51), Online publication date: 1-Jan-2014. Modery-Pawlowski C, Kuo H, Baldwin W and Gupta A (2013) A platelet-inspired paradigm for nanomedicine targeted to multiple diseases, Nanomedicine, 10.2217/nnm.13.113, 8:10, (1709-1727), Online publication date: 1-Oct-2013. Steinfeld D, Liu A, Hsu S, Chan Y, Stankus J, Pacetti S and Tai J (2012) Comparative Assessment of Transient Exposure of Paclitaxel or Zotarolimus on In Vitro Vascular Cell Death, Proliferation, Migration, and Proinflammatory Biomarker Expression, Journal of Cardiovascular Pharmacology, 10.1097/FJC.0b013e31825aa742, 60:2, (179-186), Online publication date: 1-Aug-2012. Glenn A, Bulusu K, Shu F and Plesniak M (2012) Secondary flow structures under stent-induced perturbations for cardiovascular flow in a curved artery model, International Journal of Heat and Fluid Flow, 10.1016/j.ijheatfluidflow.2012.02.005, 35, (76-83), Online publication date: 1-Jun-2012. Moreno K, Murray-Wijelath J, Yagi M, Kohler T, Hatsukami T, Clowes A and Sobel M (2011) Circulating inflammatory cells are associated with vein graft stenosis, Journal of Vascular Surgery, 10.1016/j.jvs.2011.04.039, 54:4, (1124-1130), Online publication date: 1-Oct-2011. Rendu F, Peoc'h K, Berlin I, Thomas D and Launay J (2011) Smoking Related Diseases: The Central Role of Monoamine Oxidase, International Journal of Environmental Research and Public Health, 10.3390/ijerph8010136, 8:1, (136-147) O'Donoghue M, Antman E, Braunwald E, Murphy S, Steg P, Finkelstein A, Penny W, Fridrich V, McCabe C, Sabatine M and Wiviott S (2009) The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention, Journal of the American College of Cardiology, 10.1016/j.jacc.2009.05.025, 54:8, (678-685), Online publication date: 1-Aug-2009. Villeneuve J, Block A, Le Bousse-Kerdilès M, Lepreux S, Nurden P, Ripoche J and Nurden A (2009) Tissue inhibitors of matrix metalloproteinases in platelets and megakaryocytes: A novel organization for these secreted proteins, Experimental Hematology, 10.1016/j.exphem.2009.03.009, 37:7, (849-856), Online publication date: 1-Jul-2009. de la Motte C, Nigro J, Vasanji A, Rho H, Kessler S, Bandyopadhyay S, Danese S, Fiocchi C and Stern R (2009) Platelet-Derived Hyaluronidase 2 Cleaves Hyaluronan into Fragments that Trigger Monocyte-Mediated Production of Proinflammatory Cytokines, The American Journal of Pathology, 10.2353/ajpath.2009.080831, 174:6, (2254-2264), Online publication date: 1-Jun-2009. Anitua E, Sánchez M, Zalduendo M, de la Fuente M, Prado R, Orive G and Andía I (2009) Fibroblastic response to treatment with different preparations rich in growth factors, Cell Proliferation, 10.1111/j.1365-2184.2009.00583.x, 42:2, (162-170), Online publication date: 1-Apr-2009. Koh S, Kim J, Hyun Y, Park S, Chae J, Park S, Kim J, Youn J, Jang Y and Lee J (2009) Association of serum RANTES concentrations with established cardiovascular risk markers in middle-aged subjects, International Journal of Cardiology, 10.1016/j.ijcard.2007.10.038, 132:1, (102-108), Online publication date: 1-Feb-2009. Frank M and Hester C Immune Complexes: Normal Physiology and Role in Disease Allergy Frontiers: Classification and Pathomechanisms, 10.1007/978-4-431-88315-9_6, (79-94) Sabatine M, Hamdalla H, Mehta S, Fox K, Topol E, Steinhubl S and Cannon C (2008) Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use, American Heart Journal, 10.1016/j.ahj.2007.11.020, 155:5, (910-917), Online publication date: 1-May-2008. Jang Y, Chae J, Hyun Y, Koh S, Kim J, Ko M, Rim S, Shin H, Ordovas J and Lee J (2007) The RANTES −403G>A promoter polymorphism in Korean men: association with serum RANTES concentration and coronary artery disease , Clinical Science, 10.1042/CS20070014, 113:8, (349-356), Online publication date: 1-Oct-2007. van der Linden J (2007) Pro: Continuation of Aspirin/Clopidogrel for Cardiac Surgery, Journal of Cardiothoracic and Vascular Anesthesia, 10.1053/j.jvca.2007.03.011, 21:4, (602-605), Online publication date: 1-Aug-2007. Mueller J and Wallukat G (2007) Patients who Have Dilated Cardiomyopathy Must Have a Trial of Bridge to Recovery (Pro), Heart Failure Clinics, 10.1016/j.hfc.2007.05.006, 3:3, (299-315), Online publication date: 1-Jul-2007. Danese S, Dejana E and Fiocchi C (2007) Immune Regulation by Microvascular Endothelial Cells: Directing Innate and Adaptive Immunity, Coagulation, and Inflammation, The Journal of Immunology, 10.4049/jimmunol.178.10.6017, 178:10, (6017-6022), Online publication date: 15-May-2007. Evangelista V, Pamuklar Z, Piccoli A, Manarini S, Dell'Elba G, Pecce R, Martelli N, Federico L, Rojas M, Berton G, Lowell C, Totani L and Smyth S (2006) Src family kinases mediate neutrophil adhesion to adherent platelets, Blood, 10.1182/blood-2006-06-029082, 109:6, (2461-2469), Online publication date: 15-Mar-2007. Karantonis H, Fragopoulou E, Antonopoulou S, Rementzis J, Phenekos C and Demopoulos C (2006) Effect of fast-food Mediterranean-type diet on type 2 diabetics and healthy human subjects' platelet aggregation, Diabetes Research and Clinical Practice, 10.1016/j.diabres.2005.09.003, 72:1, (33-41), Online publication date: 1-Apr-2006. Maitz M and Shevchenko N (2005) Plasma-immersion ion-implanted nitinol surface with depressed nickel concentration for implants in blood, Journal of Biomedical Materials Research Part A, 10.1002/jbm.a.30526, 76A:2, (356-365), Online publication date: 1-Feb-2006. Duraiswamy N, Jayachandran B, Byrne J, Moore J and Schoephoerster R (2005) Spatial Distribution of Platelet Deposition in Stented Arterial Models Under Physiologic Flow, Annals of Biomedical Engineering, 10.1007/s10439-005-7598-2, 33:12, (1767-1777), Online publication date: 1-Dec-2005. Okon A, Dubinsky M, Vasiliauskas E, Papadakis K, Ippoliti A, Targan S and Fleshner P (2005) Elevated Platelet Count before Ileal Pouch–Anal Anastomosis for Ulcerative Colitis is Associated with the Development of Chronic Pouchitis, The American Surgeon, 10.1177/000313480507101005, 71:10, (821-826), Online publication date: 1-Oct-2005. Mitra A, Del Core M and Agrawal D (2005) Cells, cytokines and cellular immunity in the pathogenesis of fibroproliferative vasculopathies, Canadian Journal of Physiology and Pharmacology, 10.1139/y05-080, 83:8-9, (701-715), Online publication date: 1-Aug-2005. Lindemann S, McIntyre T, Prescott S, Zimmerman G and Weyrich A Platelet Signal-Dependent Protein Synthesis Platelet Function, 10.1007/978-1-59259-917-2_6, (149-174) Engwerda C, Belnoue E, Grüner A and Rénia L (2005) ExperimentalModels of Cerebral Malaria Immunology and Immunopathogenesis of Malaria, 10.1007/3-540-29967-X_4, (103-143), . Lee M, David E, Makkar R and Wilentz J (2004) Molecular and cellular basis of restenosis after percutaneous coronary intervention: the intertwining roles of platelets, leukocytes, and the coagulation–fibrinolysis system, The Journal of Pathology, 10.1002/path.1598, 203:4, (861-870), Online publication date: 1-Aug-2004. Danese S, Motte C and Fiocchi C (2004) Platelets in Inflammatory Bowel Disease: Clinical, Pathogenic, and Therapeutic Implications, The American Journal of Gastroenterology, 10.1111/j.1572-0241.2004.04129.x, 99:5, (938-945), Online publication date: 1-May-2004. Cambien B and Wagner D (2004) A new role in hemostasis for the adhesion receptor P-selectin, Trends in Molecular Medicine, 10.1016/j.molmed.2004.02.007, 10:4, (179-186), Online publication date: 1-Apr-2004. Ghosh S, Polanowska‐Grabowska R, Fujii J, Obrig T and Gear A (2004) Shiga toxin binds to activated platelets, Journal of Thrombosis and Haemostasis, 10.1111/j.1538-7933.2004.00638.x, 2:3, (499-506), Online publication date: 1-Mar-2004. Davı̀ G, Falco A and Patrono C (2004) Determinants of F2-isoprostane biosynthesis and inhibition in man, Chemistry and Physics of Lipids, 10.1016/j.chemphyslip.2003.10.001, 128:1-2, (149-163), Online publication date: 1-Mar-2004. Quinn M, Bhatt D, Zidar F, Vivekananthan D, Chew D, Ellis S, Plow E and Topol E (2004) Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention, The American Journal of Cardiology, 10.1016/j.amjcard.2003.11.048, 93:6, (679-684), Online publication date: 1-Mar-2004. Kälvegren H, Majeed M and Bengtsson T (2003) Chlamydia pneumoniae Binds to Platelets and Triggers P-Selectin Expression and Aggregation, Arteriosclerosis, Thrombosis, and Vascular Biology, 23:9, (1677-1683), Online publication date: 1-Sep-2003. Weyrich A, Lindemann S and Zimmerman G (2003) The evolving role of platelets in inflammation, Journal of Thrombosis and Haemostasis, 10.1046/j.1538-7836.2003.00304.x, 1:9, (1897-1905), Online publication date: 1-Sep-2003. Danese S, de la Motte C, Sturm A, Vogel J, West G, Strong S, Katz J and Fiocchi C (2003) Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients, Gastroenterology, 10.1016/S0016-5085(03)00289-0, 124:5, (1249-1264), Online publication date: 1-May-2003. McIntyre T, Prescott S, Weyrich A and Zimmerman G (2003) Cell-cell interactions: leukocyte-endothelial interactions, Current Opinion in Hematology, 10.1097/00062752-200303000-00009, 10:2, (150-158), Online publication date: 1-Mar-2003. September 17, 2002Vol 106, Issue 12 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000033634.60453.22PMID: 12234942 Originally publishedSeptember 17, 2002 KeywordsleukocytesinflammationEditorialsendotheliumplateletsPDF download Advertisement
Referência(s)